Study Outcomes
Anemia, VTE, anemia
SECONDARY, ANEMIA, EVENT, ANEMIA
The primary outcome of the TRAVERSE Anemia Study was the correction of anemia, defined as an increase in hemoglobin level to 12.7 g/dL or above during the intervention period, among randomized participants who had anemia at baseline. Secondary analyses compared the risk of developing anemia postrandomization in patients who did not have anemia at baseline and the proportions of participants whose hemoglobin increased postrandomization by more than 1.0 g/dL above baseline in those with anemia. Other secondary end points included change from baseline in hemoglobin, hematocrit, red cell counts and indices, and energy and cognitive score, ascertained using the energy and cognition domains of HIS-Q. The time to first occurrence of MACE and time to first VTE event were recorded. The study also determined whether the changes in hemoglobin in testosterone-treated men were associated with improvements in energy and cognition in participants with anemia. Total testosterone, dihydrotestosterone, and estradiol concentrations were analyzed at all available time points.